UBS Group
ACHV icon

UBS Group’s Achieve Life Sciences ACHV Stock Holding History

UBS Group’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Hold
0
– -$1K – 8718
2014
Q4 		– Hold
0
– – – 9518

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's ACHV Position: Q1 2026 in Review

UBS Group increased its Achieve Life Sciences (ACHV) stake by 14% in Q1 2026, buying an estimated $182K and bringing the position to 326,270 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #5588.

UBS Group first reported a position in ACHV in Q4 2014 and has held it in 36 quarters since. The position peaked at $1.42M in Q4 2025. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

  • UBS Group held 326,270 shares of Achieve Life Sciences worth $959K as of Q1 2026.
  • UBS Group bought 41,041 Achieve Life Sciences shares in Q1 2026, an estimated $182K.
  • Achieve Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5588 holding.
  • UBS Group first reported a position in Achieve Life Sciences in Q4 2014 and has held it in 36 quarters since.
  • UBS Group's Achieve Life Sciences position peaked at $1.42M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.